Improving Medication Adherence for Recently Diagnosed Cancer Patients
Official title: Improving Adherence to Chronic Disease Medication Regimens Among Patients With Recently Diagnosed Cancer: A Pilot Study
Run by Duke University · NCT07811258 · Data updated 2026-11-12
This pilot tests whether a pharmacist-led program plus the Medisafe app helps people with newly diagnosed cancer who take multiple medicines stick to their treatment plans.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Duke University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Durham, North Carolina) |
| Status | Recruiting |
| Started | November 30, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07811258 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with breast, colorectal, lung, or prostate cancer diagnosed in the past 12 months, actively receiving cancer treatment or had recent surgery, and with at least two chronic conditions and multiple medications.
✕Probably not a fit
Patients without smartphone access, non-English speakers, or those not meeting the multimorbidity or treatment criteria may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional pilot study randomizes 30 adults diagnosed with breast, colorectal, lung, or prostate cancer within the last year to receive a pharmacist-led medication review plus the Medisafe app or usual care. The aim is to assess feasibility, acceptability, usability, and preliminary efficacy of the adherence support package in patients with multimorbidity. The intervention combines personalized medication management by a pharmacist with digital reminders and tracking through the Medisafe platform. Eligibility requires ongoing cancer treatment or recent surgical care, at least two chronic conditions, and current prescriptions beyond cancer therapy. Exclusion criteria include non-English literacy or not owning a smartphone, and the study is led by Duke University in Durham, NC.
Why it matters
Potential benefit: If successful, patients may experience better adherence to cancer-related and non-cancer medications, potentially improving treatment outcomes and quality of life.
How similar studies have gone: Prior pharmacist-led and digital adherence efforts have shown feasibility in other chronic conditions, supporting interest in this targeted cancer population, though this exact combination is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed with breast, colorectal, lung or prostate cancer in the previous 12 months * had no prior diagnosis of cancer * are currently undergoing chemotherapy or radiation and/or underwent surgery in the prior 3 months * had \>2 chronic conditions for \>1 year prior to cancer diagnosis * are prescribed \>1 non-cancer medication(s) Exclusion Criteria: * cannot read and communicate in English * do not have a smartphone
Where it's running
-
Duke University
Durham, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Deborah Kaye — Duke University
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
FlexED: A digital program to help young women see thoughts and feelings about their body in a friendlier way
This trial tests a smartphone-based, gamified ACT-inspired program called FlexED to help young women and girls at risk for eating disorders see how they think and feel about their bodies, and to see if it can be feasibly spread to more people.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
-
Lupus Nephritis Care Pathway
A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.
-
Temporal Interference Brain Stimulation for adults with drug-resistant focal epilepsy during stereo-EEG monitoring
This study tests whether a non-invasive Temporal Interference brain stimulation can reduce abnormal brain activity in adults with drug-resistant focal epilepsy who are undergoing stereo-EEG monitoring.
-
Imaging retinal structure in premature babies to guide care
This study tests whether bedside ultra-widefield eye imaging can better guide treatment decisions for retinopathy of prematurity in preterm infants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.